Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single Automated Analyzer to Bring Full Suite of Diagnostics to Wherever Patients Are

By LabMedica International staff writers
Posted on 04 May 2023

Timely and accurate diagnostics can enhance patient care by making it more informed, personalized, and proactive. More...

Now, a novel platform that delivers swift results using minimal blood volumes incorporates technology that facilitates automation and adaptable form factors outside centralized labs, bridging the gap between diagnostics and treatment.

Vital Biosciences Inc. (Mississauga, ON, Canada) is developing a single automated device designed to provide a comprehensive range of diagnostics directly to patients. The company's technology strives to make healthcare significantly more personalized, proactive, and accessible. With only 600 uL of blood, the platform can measure 50+ of the most commonly requested biomarkers in primary care within 20 minutes, without compromising analytical performance. The instrument employs an automated microfluidic workflow to simultaneously run three subsystems: hematology, clinical chemistry, and immunoassays. The platform quantifies the complete panel of biomarkers using on-board optical readers and automated sample preparation and measurement procedures that require minimal user input. This makes the platform suitable for use in CLIA-waived settings.

Vital's initial menu caters to a broad range of potential use cases for the general population, including inflammation, cardiac markers, diabetes, liver disorders, lipid disorders, post-acute event monitoring, clinical trial monitoring, chronic disease management, and proactive lifestyle management. The company aims to create a comprehensive menu that covers 100% of the tests needed for at least 90% of patients, thereby eliminating the need to send tests to a centralized lab. Patients would no longer need to travel to a draw site or ship their samples to a centralized laboratory, nor wait for days to discuss their results with their healthcare provider. Patients who are likely to require bloodwork can provide their sample at check-in and receive results during their initial appointment. Bridging this care gap will make diagnostics more accessible and accelerate clinical decision-making.

Related Links:
Vital Biosciences Inc. 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: New findings demonstrate a blood RNA signal that may indicate ovarian cancer before conventional tests detect a tumor. (Image Credit: iStock)

Blood RNA Test May Detect Precursors to Ovarian Cancer

High-grade serous ovarian cancer is often diagnosed at an advanced stage, limiting opportunities for early intervention. The disease frequently originates in the fallopian tube as serous tubal intraepithelial... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.